August 18, 2015
FOR IMMEDIATE RELEASE
CHANGE Applauds FDA for Listening to Women
WASHINGTON, D.C. – The Food and Drug Administration (FDA) this week approved Flibanserin, the first-ever medical treatment for hypoactive sexual desire disorder (HSDD) – the most common form of sexual dysfunction reported by women. The decision comes after more than a year of advocacy and outreach – including two public meetings at the FDA – from women who suffer from HSDD. In response to the FDA announcement, Serra Sippel, president of the Center for Health and Gender Equity (CHANGE) issued the following statement:
“Today we celebrate a victory for women’s sexual rights. To pursue a safe and satisfying sexual life is a human right and today marks the first time there is a medical treatment that women can choose, among other options, to address sexual dysfunction.
“Rarely do we have an opportunity to have a public conversation about sexual pleasure and the right to a fulfilling sex life. This year we celebrate the 20th anniversary of the Fourth World Conference on Women held in Beijing, China, where women’s rights advocates and national governments affirmed the rights of women and committed to gender equality. Sexual and reproductive rights – which include the right to satisfying sex – are the cornerstones to achieving gender equality and the empowerment of women and girls.
“While CHANGE does not advocate for one form of treatment over another, we do advocate for listening to women. This week’s FDA decision is about respecting a woman’s right to choose the best path forward in realizing her best sexual self.”